Symbiotec Pharmalab Q1 FY27: Consol revenue Rs 218.20 cr, PAT Rs 14.10 cr
Symbiotec Pharmalab’s Q1 FY27 consolidated revenue from operations rose to Rs 218.20 cr while PAT declined to Rs 14.10 cr versus Q1 FY26.
Key takeaways
- Revenue from Operations: Rs 218.20 cr in Q1 FY27 vs Rs 203.20 cr in Q1 FY26
- Gross Profit: Rs 142.60 cr in Q1 FY27 vs Rs 125.80 cr in Q1 FY26
- Reported EBIDTA: Rs 45.20 cr in Q1 FY27 vs Rs 58.00 cr in Q1 FY26
- PAT: Rs 14.10 cr in Q1 FY27 vs Rs 29.90 cr in Q1 FY26
- PAT Margins (%): 6% in Q1 FY27 vs 15% in Q1 FY26
Q1 FY27 · consolidated
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | Rs 218.20 cr | Rs 203.20 cr | +7.4% |
| PAT | Rs 14.10 cr | Rs 29.90 cr | -52.8% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
-
Net margin was 6.46% of revenue, down 825 bps from 14.71%.
-
Basis & period: Consolidated statement of profit & loss for Q1 FY27 (quarter ended June 30, 2026) vs Q1 FY26 (same quarter a year earlier), as per the Q1FY27 Consolidated Profit & Loss Statement in the investor presentation.
-
Revenue from Operations: Rs 218.20 cr (Q1 FY27) vs Rs 203.20 cr (Q1 FY26)
-
Gross Profit: Rs 142.60 cr (Q1 FY27) vs Rs 125.80 cr (Q1 FY26)
-
Gross Margins (%): 65% (Q1 FY27) vs 62% (Q1 FY26)
-
Reported EBIDTA: Rs 45.20 cr (Q1 FY27) vs Rs 58.00 cr (Q1 FY26)
-
Reported EBIDTA Margin (%): 21% (Q1 FY27) vs 29% (Q1 FY26)
-
EBIT: Rs 23.70 cr (Q1 FY27) vs Rs 50.10 cr (Q1 FY26)
-
Finance Cost: Rs 6.20 cr (Q1 FY27) vs Rs 5.30 cr (Q1 FY26)
-
Profit Before Tax: Rs 17.50 cr (Q1 FY27) vs Rs 44.80 cr (Q1 FY26)
-
Tax Expenses: Rs 3.50 cr (Q1 FY27) vs Rs 14.90 cr (Q1 FY26)
-
Profit After Tax (PAT): Rs 14.10 cr (Q1 FY27) vs Rs 29.90 cr (Q1 FY26)
-
PAT Margins (%): 6% (Q1 FY27) vs 15% (Q1 FY26)
According to the Q1FY27 Consolidated Profit & Loss Statement in the investor presentation, consolidated revenue from operations for Q1 FY27 was Rs 218.20 cr, up from Rs 203.20 cr in Q1 FY26. Gross Profit increased to Rs 142.60 cr from Rs 125.80 cr, with Gross Margins (%) moving to 65% from 62%.
The company reported Reported EBIDTA of Rs 45.20 cr in Q1 FY27 versus Rs 58.00 cr in Q1 FY26, and Reported EBIDTA Margin (%) of 21% compared with 29% a year earlier. The table also breaks out operating expenses and depreciation between the API business and new businesses, but the consolidated profitability figures above are taken directly from the same statement.
Further down the same table, EBIT stood at Rs 23.70 cr in Q1 FY27 against Rs 50.10 cr in Q1 FY26. Finance Cost rose to Rs 6.20 cr from Rs 5.30 cr. Profit Before Tax was Rs 17.50 cr in Q1 FY27, compared with Rs 44.80 cr in Q1 FY26, while Tax Expenses were Rs 3.50 cr versus Rs 14.90 cr.
After tax, Profit After Tax (PAT) for Q1 FY27 was Rs 14.10 cr, down from Rs 29.90 cr in Q1 FY26, and PAT Margins (%) were 6% versus 15%. All these figures are transcribed from the consolidated profit and loss summary presented as the Q1FY27 Consolidated Profit & Loss Statement in the investor presentation.
Track Symbiotec Pharmalab Ltd
Cruxal reads every Symbiotec Pharmalab Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
